OMER ▲ +4.9% - Omeros Corporation $OMER Cantor Fitzgerald upgraded Omeros to Overweight from Neutral with a $22 price target. The left the company's Q2 report with the belief that Yartemlea is having a much better than expected launch. After talking to physicians, Cantor is "increasingly convinced" Yartemlea can be a bigger drug than it appreciated. Physician feedback has been largely positive, pointing to 30%-40% market share over time, the analyst tells investors in a research note. Cantor upped its peak sales estimate to $400M. Omeros Corporation rose 4.9% today after Cantor Fitzgerald upgraded the stock to Overweight from Neutral and raised its price target to $22, citing stronger-than-expected early traction for Yartemlea. The analyst's upgrade was driven by positive physician feedback following the company's Q2 report, with Cantor now modeling the drug could capture 30%-40% market share and generate peak sales of $400 million, significantly above its prior expectations. 22-SEP-2026 09:02 AM ET